✦ LIBER ✦

Amantadine in Huntington's disease: open-label video-blinded study

✍ Scribed by C. Lucetti; G. Gambaccini; S. Bernardini; G. Dell'Agnello; L. Petrozzi; G. Rossi; U. Bonuccelli

Book ID: 106269717
Publisher: Springer Milan
Year: 2002
Tongue: English
Weight: 34 KB
Volume: 23
Category: Article
ISSN: 1590-1874
DOI: 10.1007/s100720200081

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Olanzapine for Huntington's disease: An

Olanzapine for Huntington's disease: An open label study

✍ R.M. Bonelli; P. Hofmann 📂 Article 📅 2002 🏛 Elsevier Science 🌐 English ⚖ 123 KB

Riluzole in Huntington's disease (HD): a

Riluzole in Huntington's disease (HD): an open label study with one year follow up

✍ Klaus Seppi; Joerg Mueller; Thomas Bodner; Elisabeth Brandauer; Thomas Benke; He 📂 Article 📅 2001 🏛 Springer 🌐 English ⚖ 163 KB

Open-label pilot study of levetiracetam

Open-label pilot study of levetiracetam (Keppra) for the treatment of chorea in Huntington's disease

✍ Theresa A. Zesiewicz; Kelly L. Sullivan; Robert A. Hauser; Juan Sanchez-Ramos 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 65 KB 👁 1 views

## Abstract The objective of this study is to evaluate the tolerability and preliminary efficacy of levetiracetam (LEV) in reducing chorea in Huntington's disease (HD) patients in a prospective open‐label pilot study. Nine HD patients with chorea were treated with LEV in doses up to 3,000 mg/day fo

Tetrabenazine as anti-chorea therapy in

Tetrabenazine as anti-chorea therapy in Huntington Disease: an open-label continuation study. Huntington Study Group/TETRA-HD Investigators

✍ Samuel Frank 📂 Article 📅 2009 🏛 BioMed Central 🌐 English ⚖ 638 KB

Management of punding in Parkinson’s dis

Management of punding in Parkinson’s disease: an open-label prospective study

✍ A. Fasano; L. Ricciardi; M. Pettorruso; A. R. Bentivoglio 📂 Article 📅 2010 🏛 Springer 🌐 English ⚖ 141 KB

CQP 201-403 in Parkinson's disease: An o

CQP 201-403 in Parkinson's disease: An open-label pilot study

✍ Dr. Ronald F. Pfeiffer; Leonel H. Herrera; Carolyn S. Glaeske; Ruth E. Hofman 📂 Article 📅 1989 🏛 John Wiley and Sons 🌐 English ⚖ 249 KB 👁 1 views

The dopamine agonist, CQP 201-403, was administered to 10 patients in an open label fashion with rapid dosage escalation during hospitalization. Assessed over a n average of 20 days, significant improvement occurred in bradykinesia, rigidity, and postural instability. Tremor did not occur in suffici